Biotronik has announced the first in-human implantations in the BIO-Master.CSP study examining the use of the company’s investigational, next-generation Solia conduction system pacing (CSP) S pacing lead when implanted in the left bundle branch area (LBBA).
LBBA pacing is an emerging technique providing a more physiologic activation of cardiac tissue in patients needing ventricular pacing support—a pacing site that may also help avoid the detrimental effects of traditional right ventricular pacing, according to Biotronik.
The company also claims that—building on the “strong experience” of Solia S in LBBA pacing—the Solia CSP S lead variant has been designed with a fixed helix for simpler preparation, a lengthened helix for ease of LBBA access, and an optimised distal end for high durability.
The first system has been implanted at the Auckland City Hospital (Auckland, New Zealand) by cardiac electrophysiologist Matthew O’Connor.
“It was great to see how smoothly the case went,” O’Connor stated. “The lead performed perfectly and I’m looking forward to future implants. I appreciate a lot of work and many months and years of work go into these things. For me as an implanting physician, it is very satisfying to see a finished product that works this nicely.”
The BIO-Master.CSP trial seeks to demonstrate the safety and effectiveness of the Biotronik Solia CSP S investigational pacing lead used in the LBBA. Successful lead implant and user satisfaction, as well as long-term performance, will be assessed.
“There’s little doubt that left bundle branch area pacing is an opportunity for improved care for many patients compared to traditional apical pacing,” said David Hayes, chief medical officer of Biotronik. “I believe the research and innovation behind Solia CSP S is yet another example of Biotronik’s commitment to partnering with our physician customers to develop novel products and solutions to meet their needs.”
